Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 1.00 |
| ▸ | PPARD | Q03181 | 10/20 | 1.00 |
| ▸ | PPARA | Q07869 | 10/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.57 |
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6861995 | 1.00 | PPARG (1.00) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6938524 | 0.94 | PPARG (0.89) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6938540 | 0.94 | PPARG (0.89) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6937815 | 0.94 | PPARG (0.88) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6934092 | 0.93 | PPARG (0.86) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6935493 | 0.92 | PPARG (0.85) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6936719 | 0.92 | PPARG (0.85) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6938779 | 0.92 | PPARG (0.85) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6938775 | 0.92 | PPARG (0.85) | PPARGPPARDPPARANR1H2NR1H3 | |
| SCHEMBL6933836 | 0.91 | PPARG (0.84) | PPARGPPARDPPARANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171692-A1 | Modulation of bone formation | ANDREW SCUTT (GB) | 2004-09-02 | — | — | US | claimed |
| JP-2003522787-A | — | — | 2003-07-29 | — | — | JP | claimed |
| US-20030139372-A1 | Modulation of bone formation | UNIVERSITY OF SHEFFIELD (GB) | 2003-07-24 | — | — | US | claimed |
| EP-0888278-B1 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2003-07-23 | — | — | EP | claimed |
| EP-1259233-A1 | MODULATION OF BONE FORMATION | THE UNIVERSITY OF SHEFFIELD (GB) | 2002-11-27 | — | — | EP | claimed |
| WO-2001060355-A1 | MODULATION OF BONE FORMATION | UNIVERSITY OF SHEFFIELD (GB) | 2001-08-23 | — | — | WO | claimed |
| EP-0888278-A4 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 1999-06-30 | — | — | EP | claimed |
| EP-0888278-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997028115-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | claimed |
| US-20040171692-A1 | Modulation of bone formation | ANDREW SCUTT (GB) | 2004-09-02 | — | — | US | disclosed |
| US-20030139372-A1 | Modulation of bone formation | UNIVERSITY OF SHEFFIELD (GB) | 2003-07-24 | — | — | US | disclosed |
| EP-0888278-B1 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-0888278-A4 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 1999-06-30 | — | — | EP | disclosed |
| EP-0888278-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997028115-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |